GEN Exclusives

More »

GEN News Highlights

More »
Jan 8, 2007

Catalyst and Wyeth Ink Agreements Worth Up To $100M

  • Catalyst Biosciences signed two agreements with Wyeth Pharmaceuticals with potential payments of up to $100 million plus royalties. The research collaboration and license agreements support discovery and preclinical development using Catalyst's Alterase™ therapeutics platform (engineered human proteases) directed at a target in metabolic disease and one in oncology.

    Wyeth will be responsible for the clinical development, manufacturing, and marketing of products developed as a result of these collaborations. The deal includes an upfront license payments, milestone payments, R&D funding, and royalties on product sales.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?